SCHEMBL1471268

SCHEMBL1471268

[c]1n[nH]cc1N1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HTT P42858 3/20 0.35
MEN1 O00255 1/20 0.35
RECQL P46063 1/20 0.35
KMT2A Q03164 1/20 0.35
ATM Q13315 1/20 0.35
HRH1 P35367 1/20 0.34
INMT O95050 1/20 0.33
HPGD P15428 1/20 0.33
MAPT P10636 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
CHKA P35790 1/20 0.31
ALDH1A1 P00352 2/20 0.31
NPSR1 Q6W5P4 2/20 0.31
BCHE P06276 1/20 0.31
ACHE P22303 1/20 0.31
CYP1A2 P05177 1/20 0.31
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4638253 0.98 HRH1 (0.35) USP2SMN1; SMN2TDP1HTTMEN1
SCHEMBL17654278 0.93
SCHEMBL7380677 0.72
SCHEMBL1854770 0.71 CYP1A2 (0.43) TDP1HRH1CYP1A2
SCHEMBL6839409 0.64 HPGD (0.32) HPGDCHKAALDH1A1LMNA
SCHEMBL1852700 0.63 CHKA (0.38) USP2SMN1; SMN2TDP1HTTMEN1
SCHEMBL185803 0.63 HPGD (0.39) SMN1; SMN2TDP1MEN1KMT2AHPGD
SCHEMBL3432719 0.61 NOTUM (0.40) SMN1; SMN2HTTMEN1KMT2AMAPT
SCHEMBL2992722 0.61 CYP1A2 (0.42) USP2SMN1; SMN2TDP1HTTHPGD
SCHEMBL6751496 0.61 ALDH1A1 (0.33) USP2SMN1; SMN2TDP1HTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 US claimed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 EP claimed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 US claimed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO claimed
WO-2009071888-A1 PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO claimed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO claimed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO claimed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 EP claimed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 WO claimed
US-9044413-B2 Block polymers, compositions and methods for use for foams, laundry detergents, and shower rinses and coagulants SOLVAY USA INC. (US) 2015-06-02 US disclosed
US-8907033-B2 Polymers, compositions and methods of use for foams, laundry detergents, shower rinses and coagulants SOLVAY USA INC. (US) 2014-12-09 US disclosed
EP-1322684-B1 PROCESSES TO CONTROL THE RESIDUAL MONOMER LEVEL OF COPOLYMERS OF TERTIARY AMINO MONOMER WITH A VINYL-FUNCTIONAL MONOMER SOLVAY USA INC (US) 2014-05-07 EP disclosed
US-20140034076-A1 POLYMERS, COMPOSITIONS AND METHODS OF USE FOR FOAMS, LAUNDRY DETERGENTS, SHOWER RINSES AND COAGULANTS RHODIA INC. (US) 2014-02-06 US disclosed
US-8580905-B2 Polymers, compositions and methods of use for foams, laundry detergents, shower rinses and coagulants RHODIA INC. (US) 2013-11-12 US disclosed
WO-2000029540-A1 ULTRASONIC CLEANING COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2000-05-25 WO disclosed
WO-2000029535-A1 CLEANING PRODUCT WHICH USES SONIC OR ULTRASONIC WAVES THE PROCTER & GAMBLE COMPANY (US) 2000-05-25 WO disclosed
WO-2000028874-A2 ULTRASONIC CLEANING DEVICE THE PROCTER & GAMBLE COMPANY (US) 2000-05-25 WO disclosed
WO-1999027058-A1 DETERGENT COMPOSITIONS COMPRISING POLYMERIC SUDS ENHANCERS AND THEIR USE THE PROCTER & GAMBLE COMPANY (US) 1999-06-03 WO disclosed
WO-1999027057-A1 LIQUID DETERGENT COMPOSITIONS COMPRISING POLYMERIC SUDS ENHANCERS THE PROCTER & GAMBLE COMPANY (US) 1999-06-03 WO disclosed
US-5869225-A Processing method of silver halide photographic light sensitive material KONICA CORPORATION (JP) 1999-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA USP2 3231/4885SMN1; SMN2 1521/4885TDP1 533/4885
US-20140034076-A1 POLYMERS, COMPOSITIONS AND METHODS OF USE FOR FOAMS, LAUNDRY DETERGENTS, SHOWER RINSES AND COAGULANTS DSG1, DSTN, CUTA USP2 569/4885SMN1; SMN2 1228/4885TDP1 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.